RPS25A Antibody

What is RPS25 and what is its function in cells?

RPS25 (40S ribosomal protein S25) is an essential component of the small (40S) ribosomal subunit. The protein functions as part of the ribosome, the large ribonucleoprotein complex responsible for protein synthesis in cells . More specifically, RPS25 is a eukaryotic-specific, non-essential protein component that plays critical roles in several forms of unconventional translation, including Internal Ribosome Entry Site (IRES)-mediated translation and ribosomal shunting .

The protein is particularly significant for its role in mediating direct recruitment of the 40S ribosomal subunit to specific RNA structures, such as the Cricket Paralysis Virus IRES RNA . Additionally, it regulates translation initiation of hepatitis C virus and picornaviral IRES RNAs downstream of 40S subunit recruitment . Beyond viral translation mechanisms, RPS25 also regulates several cellular IRES-containing RNAs, including those for p53 and c-myc .

What experimental applications are supported by commercial RPS25A antibodies?

Commercial RPS25A antibodies support multiple experimental applications across different research contexts. The table below summarizes the validated applications for commonly available antibodies:

These antibodies have been tested in various experimental contexts, with demonstrated reliability for detecting RPS25 protein across multiple applications . The ZooMAb rabbit monoclonal antibody offers enhanced specificity, affinity, reproducibility, and stability compared to conventional monoclonals, which may be advantageous for certain sensitive applications .

What species reactivity do common RPS25A antibodies demonstrate?

The species reactivity of RPS25A antibodies varies by product, with some showing broad cross-reactivity while others are more species-specific. Based on the search results, the following reactivity patterns have been confirmed:

• ab254671: Reacts with Human, Mouse, and Rat samples

• ab111936: Reacts with Human samples

• ZooMAb 3G15: Validated in Rat liver tissue lysate, A549 (human) and NIH3T3 (mouse) cell lysates

This cross-reactivity is likely due to the high conservation of RPS25 protein sequence across mammalian species. When selecting an antibody for your experiments, consider the species of your experimental model and choose an antibody with validated reactivity for that species .

What cellular localization pattern is typically observed when using RPS25A antibodies?

RPS25A antibodies typically reveal a cytoplasmic and perinuclear localization pattern consistent with ribosomal distribution. In immunocytochemistry and immunofluorescence experiments, RPS25 is predominantly detected in the cytoplasm where ribosomes are abundant, with particular enrichment in areas of active protein synthesis .

For example, using the ab254671 antibody in ICC/IF experiments on PFA-fixed, Triton X-100 permeabilized A-431 cells (human epidermoid carcinoma cell line), RPS25 labeling is visualized primarily in the cytoplasm at a working concentration of 4μg/ml . Similar patterns have been observed with the ZooMAb 3G15 antibody in HT-29 and U2OS cells at a 1:100 dilution .

When performing tissue immunohistochemistry, RPS25 staining is typically observed throughout tissue sections with varying intensities depending on the protein synthesis activity of different cell types within the tissue .

How does RPS25 regulate RAN translation in neurodegenerative disease models?

RPS25 plays a crucial role in regulating Repeat-Associated Non-AUG (RAN) translation, particularly in the context of nucleotide repeat expansions associated with neurodegenerative diseases. Research has demonstrated that RPS25 is selectively required for efficient RAN translation of expanded GGGGCC repeat expansions in the C9orf72 gene (associated with ALS/FTD) and CAG expansions in ATXN2 and HTT genes .

Mechanistically, genetic knockout or knockdown studies have revealed that:

• Deletion of RPS25A (rps25AΔ) in yeast reduced levels of RAN-translated poly(GP) by approximately 50% compared to wildtype yeast, without affecting the levels of GFP or the abundance of GGGGCC repeat RNA .

• In human cells (Hap1) with CRISPR-induced knockout of RPS25, RAN translation products from a 66 repeat construct showed:

  • ~50% reduction in poly(GP) levels

  • 90% reduction in Glycine-Alanine (GA) frame products

  • ~30% reduction in Glycine-Arginine (GR) levels
    These effects occurred without affecting repeat RNA levels .

• In HeLa cells with CRISPR-induced mutation in RPS25, both poly(A) and poly(Q) products from ATXN2 CAG repeats were reduced .

• RPS25 knockdown reduced poly(GP) levels in C9orf72 repeat-expressing Drosophila and significantly increased their lifespan without affecting flies expressing ATG-driven dipeptide repeats, indicating RPS25 functions at the translation level .

Importantly, RPS25 reduction did not significantly alter canonical translation, as evidenced by minimal effects on polysome profiles and expression of ATG-initiated reporters, suggesting its specific role in unconventional translation mechanisms .

What methodological considerations are important when studying RPS25 in C9orf72 repeat expansion models?

When studying RPS25 in the context of C9orf72 repeat expansions, several methodological considerations are critical for experimental design and interpretation:

• Model selection:

  • Cell models: iPSCs from ALS patients with C9orf72 expansions provide physiologically relevant contexts .

  • Animal models: Drosophila expressing GGGGCC repeats offer efficient in vivo systems to study RPS25's effects on lifespan and pathology .

• RPS25 manipulation strategies:

  • Genetic approaches: CRISPR-induced knockout/mutation provides complete elimination of RPS25 .

  • RNAi approaches: siRNA or shRNA for temporary, partial reduction of RPS25 levels .

  • Antisense oligonucleotides (ASOs): Two independent ASOs targeting RPS25 have shown efficacy in reducing RPS25 levels while preserving some translation function .

• Validation measurements:

  • RNA foci quantification: Important to confirm RPS25 manipulation doesn't affect RNA transcription, stability, or foci formation .

  • C9orf72 transcript variant measurements: RT-qPCR to verify RPS25 reduction doesn't alter expression of C9orf72 transcript variants, including those harboring the GGGGCC repeat .

  • Endogenous C9orf72 protein expression: Western blot to confirm unaltered expression of the normal protein .

• Dipeptide repeat protein (DPR) detection:

  • Different DPRs require specific detection methods, as they show varying levels of reduction upon RPS25 manipulation (e.g., poly(GA) frame showed >90% reduction while poly(GR) showed ~30% reduction) .

  • Background signal varies between assays for different DPRs, requiring appropriate controls .

• Polysome profiling:

  • Important for distinguishing effects on global translation versus RAN translation .

  • Analysis of RNA association with different polysome fractions provides insights into translation efficiency of specific transcripts .

How can RPS25 be targeted as a potential therapeutic approach for ALS/FTD?

Research suggests that inhibiting RPS25 function could be a promising therapeutic strategy for c9ALS/FTD and potentially other neurodegenerative diseases caused by nucleotide repeat expansions. Several experimental approaches demonstrate this potential:

What experimental protocols are recommended for validating RPS25 knockdown efficiency?

Validating RPS25 knockdown efficiency is critical for experiments investigating its role in RAN translation and potential therapeutic applications. Based on the research methodologies presented in the search results, the following protocols are recommended:

• Protein level validation:

  • Western blotting: Using validated anti-RPS25 antibodies (such as ab254671 at 0.4 μg/mL or ZooMAb 3G15 at 1:1,000 dilution) to quantify protein reduction .

  • Recommended cell lysates: Total cell lysates from targeted cells compared with control cells.

  • Loading controls: Use stable ribosomal proteins not affected by your manipulation, or standard housekeeping proteins like ACTB.

• Functional validation:

  • Polysome profiling: To assess effects on global translation and identify potential compensatory mechanisms .

  • Analysis of 40S/60S/polysome ratios: RPS25 knockout shows minimal changes in most profile ratios with slight increases in 60S/40S and heavy polysome/40S ratios .

  • RT-qPCR from polysome fractions: To verify translation efficiency of specific transcripts (e.g., ACTB, GFP as controls) .

• Reporter assays:

  • Canonical translation: Use ATG-initiated reporters (e.g., ATG-Clover) to confirm preservation of conventional translation .

  • RAN translation: Use reporters with nucleotide repeats (GGGGCC or CAG) lacking ATG start codons to assess specific effects on RAN translation .

  • Quantification methods: Western blotting, fluorescence microscopy, or ELISA-based detection of dipeptide repeat proteins .

• Effect on RAN translation in disease models:

  • Measure RAN translation products: Quantify poly(GP), poly(GA), poly(GR) levels in C9orf72 models or poly(A), poly(Q) in CAG repeat models .

  • RNA foci quantification: Ensure knockdown doesn't affect RNA production or foci formation .

  • C9orf72 transcript variant analysis: Verify unaltered expression patterns of disease-relevant transcripts .

How do you distinguish between effects on canonical translation versus RAN translation when manipulating RPS25 levels?

Distinguishing between effects on canonical translation versus RAN translation is essential when manipulating RPS25 levels. Research has established several approaches to make this distinction:

• Parallel reporter systems:

  • Compare effects on RAN translation reporters (containing nucleotide repeats without ATG start codons) with canonical translation reporters (containing ATG start codons) .

  • For example, studies showed RPS25 knockout did not significantly alter expression of an ATG-Clover reporter while substantially reducing RAN translation products .

  • For CAG repeat expansions, compare effects on poly(Q) initiated from the native ATG codon (e.g., in HTT) versus poly(A) RAN products from the same construct .

• Polysome profiling analysis:

  • Assess global translation through polysome profile analysis, which provides a comprehensive view of actively translating ribosomes .

  • RPS25 knockout shows only mild effects on polysome profiles, with most profile peak to 40S ratios remaining similar .

  • Analyze the association of specific mRNAs with different polysome fractions through RT-qPCR to determine translation efficiency of individual transcripts .

• Control experiments with ATG-driven dipeptide repeats:

  • Use constructs expressing the same dipeptide repeat proteins but driven from an ATG start codon rather than through RAN translation .

  • For example, RpS25 RNAi in Drosophila rescued GGGGCC repeat-expressing flies but not flies expressing ATG-driven 36GR dipeptide repeats .

  • This control directly demonstrates that RPS25 functions at the level of RAN translation rather than downstream of dipeptide repeat protein production .

• Endogenous protein expression analysis:

  • Measure levels of endogenously expressed proteins that rely on canonical translation (e.g., C9orf72 protein itself) .

  • Research showed RPS25 reduction did not alter endogenous C9orf72 protein expression while significantly reducing RAN-translated products .

• Transcript variant analysis:

  • Quantify different transcript variants to ensure observed effects are not due to altered transcription or RNA processing .

  • RT-qPCR for C9orf72 transcript variants, including those specifically harboring the GGGGCC repeat, showed no significant changes upon RPS25 reduction .

The research consistently demonstrates that while RPS25 is critical for efficient RAN translation of nucleotide repeat expansions, it has minimal impact on global canonical translation, suggesting it functions as a selective regulator of unconventional translation mechanisms .

What are the most significant recent findings regarding RPS25A antibodies in neurodegenerative disease research?

The most significant recent findings center on the critical role of RPS25 in regulating RAN translation of nucleotide repeat expansions associated with neurodegenerative diseases. Research has established RPS25 as a selective regulator of RAN translation without significantly affecting global canonical translation .

Key discoveries include:

• The selective requirement of RPS25 for efficient RAN translation of expanded GGGGCC repeat expansions in the C9orf72 gene (associated with ALS/FTD) and CAG expansions in ATXN2 and HTT genes .

• The demonstration that RPS25 reduction can mitigate neurodegenerative phenotypes in multiple model systems, including:

  • Increased survival of C9orf72 repeat-expressing Drosophila

  • Enhanced survival of induced motor neurons from C9ALS patients after glutamate challenge

  • Reduced poly(GR) and poly(PR) foci in c9ALS patient-derived iMNs

• The identification of RPS25 as a potential therapeutic target for c9ALS/FTD and possibly other neurodegenerative diseases caused by nucleotide repeat expansions .

These findings suggest that strategies to inhibit the function of RPS25 could be pursued as effective therapies for these currently untreatable conditions, representing a significant advance in the field .

What technical challenges remain in optimizing RPS25A antibodies for neurodegenerative disease research?

Despite the promising advances in understanding RPS25's role in neurodegenerative diseases, several technical challenges remain in optimizing antibody-based approaches for this research:

• Specificity for different dipeptide repeat products:

  • Current antibody-based detection methods show varying sensitivities for different RAN translation products (e.g., higher background signal for poly(GR) detection compared to poly(GP) or poly(GA)) .

  • Development of more specific antibodies against various dipeptide repeat products would enhance detection sensitivity and specificity.

• Quantitative measurements in patient-derived tissues:

  • Improving antibody-based quantification methods for low-abundance RAN translation products in patient-derived tissues remains challenging.

  • Optimizing immunohistochemical protocols for detecting both RPS25 and dipeptide repeat proteins in post-mortem brain tissue would advance translational research.

• Distinguishing between RPS25 variants:

  • Developing antibodies that can distinguish between potential post-translational modifications or variants of RPS25 that might differentially affect RAN translation.

• Monitoring therapeutic efficacy:

  • Creating antibody-based assays that can reliably monitor the efficacy of RPS25-targeting therapies in clinical samples.

  • Developing companion diagnostic approaches using anti-RPS25 antibodies to identify patients most likely to benefit from RPS25-targeting therapies.

Addressing these challenges will require continued refinement of antibody technologies and detection methods specifically optimized for neurodegenerative disease research contexts.

What future research directions might emerge from the current understanding of RPS25's role in translation?

The discovery of RPS25's selective role in RAN translation opens several promising research directions:

• Structural biology approaches:

  • Determining the precise structural basis for RPS25's role in RAN translation versus canonical translation.

  • Identifying specific domains or interactions that could be selectively targeted for therapeutic development.

• Expanded therapeutic applications:

  • Testing RPS25-targeting approaches in additional neurodegenerative diseases involving nucleotide repeat expansions beyond C9orf72 ALS/FTD.

  • Exploring combinatorial approaches targeting both RPS25 and other disease mechanisms.

• Mechanistic investigations:

  • Further elucidating how RPS25 specifically facilitates initiation at non-AUG codons in repeat expansions.

  • Identifying potential cofactors or modifiers that influence RPS25's role in RAN translation.

• Translational research:

  • Developing biomarkers based on RPS25 activity or RAN translation products for early disease detection.

  • Designing clinically viable RPS25-targeting therapeutics with optimal safety profiles.

• Broader implications for ribosome heterogeneity:

  • Investigating whether specialized ribosomes lacking RPS25 exist naturally as regulatory mechanisms.

  • Exploring whether other ribosomal proteins show similar selectivity for specific translation mechanisms.